Clinical trials: Methylprednisolone
Active Rheumatoid Arthritis
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
The purpose of this study is to compare the efficacy and safety of adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis.
- Trial name
- NCT03172325
- Testing
- Adalimumab, Methotrexate, Folic Acid
- Where
- 10 sites in Iran
- Volunteers
- 136 people
- Sponsor
- Cinnagen
Metastatic Castration-resistant Prostate Cancer
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer/androgen pathway modulator refractory (mCRPC/APMR). Current treatment for mCRPC includes chemotherapy, such as docetaxel.
- Trial name
- TroFuse-01A (NCT07908524)
- Testing
- Sacituzumab tirumotecan, Rescue medication, Docetaxel
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Lupus Nephritis
A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
This 2 arm study will compare the efficacy and safety of CellCept plus corticosteroids, versus cyclophosphamide plus corticosteroids in the induction phase followed by azathioprine in the maintenance phase, in maintaining…
- Trial name
- NCT00425438
- Testing
- Mycophenolate Mofetil, Corticosteroids, Azathioprine
- Where
- 11 sites in China
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Graft-Versus-Host Disease
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)
A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.
- Trial name
- NCT00806208
- Testing
- MEDI-507
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- MedImmune LLC
Rheumatoid Arthritis
A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA
This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects with Rheumatoid…
- Trial name
- NCT00747214
- Testing
- CRx-102, DMARD Therapy
- Volunteers
- 59 people
- Sponsor
- Zalicus
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
Healthy Volunteers
Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort
The primary objective of the study is to determine the potential effects of multiple doses of rifampin and clarithromycin on the single dose pharmacokinetics (PK) of the deflazacort active metabolite (21 desacetyl-DFZ) in healthy…
- Trial name
- NCT02286635
- Testing
- Deflazacort and rifampin, Deflazacort and Clarithromycin
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- PTC Therapeutics
Kidney Transplantation
A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation
The patients about to undergo kidney transplantation will be randomized to one of the following two group: Group FK506MR: FK506MR/MMF/steroid; Group Prograf® : Prograf® /MMF/steroid. The treatment period is 3 months( 12 weeks)
- Trial name
- NCT00481819
- Testing
- FK506MR, Prograf, Mycophenolate Mofetil
- Where
- 9 sites in China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Inc
End Stage Renal Disease, Renal Transplant
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response.
- Trial name
- NCT01154387
- Testing
- Anti-Thymocyte Globulin, TOL101, Steroids
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- Tolera Therapeutics, Inc
Asthma
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)
This study compares the 12-week efficacy and 24-week safety of mometasone furoate/formoterol fumarate (MF/F) 100/10 mcg and mometasone furate (MF) 100 mcg, both administered twice daily (BID) via metered-dose inhaler (MDI) in…
- Trial name
- NCT02741271
- Testing
- MF MDI 100 mcg BID (Open Label), MF/F MDI 100/10 mcg BID, MF MDI 100 mcg BID
- Volunteers
- 181 people
- Sponsor
- Organon and Co
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
This is a study of the overall safety, tolerability, and pharmacokinetics (PK) of MK-8808 versus rituximab (MabThera® and Rituxan®) in participants with moderate to severe RA with an inadequate response or intolerance to…
- Trial name
- NCT01390441
- Testing
- MK-8808, MabThera® (rituximab), Methotrexate
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Gout
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
The overall objective of the study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of the concomitant use of pegloticase with methotrexate (MTX) to enhance the response rate seen with pegloticase alone…
- Trial name
- MIRROR OL (NCT03635957)
- Testing
- Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Amgen
Pulmonary Disease, Chronic Obstructive
Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients
This study will assess the effects of single oral doses of SB681323 and prednisolone on biomarkers in induced sputum and blood COPD patients
- Trial name
- NCT00380133
- Testing
- SB681323, Prednisolone
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Optic Neuritis
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
- Trial name
- PIONEER-1 (NCT07623668)
- Testing
- Privosegtor, Methylprednisolone
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Oculis
Cataract
Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery.
- Trial name
- NCT02547623
- Testing
- Dexamethasone, Prednisolone
- Where
- 11 sites in United States
- Volunteers
- 194 people
- Sponsor
- ICON Bioscience Inc
Multiple Sclerosis, Relapsing-Remitting
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus…
- Trial name
- INCREASE (NCT03387046)
- Testing
- D-aspartate, IFN beta-1a, Methylprednisolone
- Where
- 17 sites in Italy
- Volunteers
- 7 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Immune System Disorder
Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates. Phase 2: To evaluate the efficacy of isatuximab in desensitization of participants awaiting kidney…
- Trial name
- NCT04294459
- Testing
- Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent
- Where
- 6 sites in United States, Spain
- Volunteers
- 23 people
- Sponsor
- Sanofi
Liver Transplantation
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
Comparison of 3 dosing regimens of Advagraf to determine if there is a dosing regimen which may have the potential to cause fewer kidney problems.
- Trial name
- DIAMOND (NCT01011205)
- Testing
- Advagraf, Mycophenolate Mofetil, Basiliximab
- Where
- 72 sites in Argentina, Austria and 21 more
- Volunteers
- 893 people
- Sponsor
- Astellas Pharma Inc
Anterior Uveitis
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- NCT01505088
- Testing
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution
- Where
- 39 sites in United States
- Volunteers
- 193 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.